Abstracts tagged "giant cell arteritis"

Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Rebecca Kuan¹, Christopher Redmond¹, McKella Sylvester², Mary Maclean¹, Francoise Meylan¹, Marcela Ferrada¹, Kaitlin Quinn¹ and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Colgate University, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…
Abstract Number: 1647 • ACR Convergence 2023
Association Between Vascular FDG Uptake at Diagnosis and Evolution in Aortic Dimensions in Giant Cell Arteritis: A Prospective Study
Lien Moreel¹, Walter Coudyzer², Lennert Boeckxstaens³, Albrecht Betrains¹, Geert Molenberghs⁴, Steven Vanderschueren¹, Eveline Claus², Koen Van Laere⁵ and Daniel Blockmans¹, ¹Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ²Department of Radiology, University Hospitals Leuven, Leuven, Belgium, ³Department of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium, ⁴Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), University of Leuven and Hasselt University, Leuven, Belgium, ⁵Department of Nuclear Medicine, University Hospitals Leuven,Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium
Background/Purpose: Patients with giant cell arteritis (GCA) have an increased risk of developing thoracic aortic aneurysms. Retrospective studies have shown that 18F-fluorodeoxyglucose (FDG) uptake in…
Abstract Number: 2393 • ACR Convergence 2023
CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap
andre ramon¹, helene Greigert², adrien guilloteau³, claudie cladière⁴, marion ciudad⁵, Sylvain Audia⁶, paul ornetti⁷, jean-Francis Maillefert⁷, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Methodological Support Unit (USMR), Dijon-Bourgogne University Hospital, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France, ⁷Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are frequently overlapping conditions. It is estimated that 16 to 21% of PMR patients have GCA.…
Abstract Number: 2410 • ACR Convergence 2023
Tocilizumab versus Methotrexate in Giant Cell Arteritis: A Retrospective Study to Compare Efficacy and Rapidity of These Steroid-sparing Agents in GCA Patients
Luca Quartuccio Quartuccio¹, Elena Treppo², Maria De Martino³, Maria Pillon¹, Simone Perniola⁴, Dario Bruno⁴, Miriam Isola³ and Elisa Gremese⁴, ¹Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ²Physician, Moimacco, Italy, ³Institute of Statistics, Department of Medicine, University of Udine, Udine, Italy, ⁴Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy
Background/Purpose: Glucocorticoids (GCs) are still the mainstay of treatment of Giant Cell Arteritis (GCA). Although GCs are highly effective in GCA, it is well documented…
Abstract Number: 2561 • ACR Convergence 2023
The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group
Alessandro Tomelleri¹, Corrado Campochiaro², Francesco Muratore³, Sara Monti⁴, Nicola Farina⁵, Chiara Marvisi⁶, Elena Galli⁷, Alessandra Milanesi⁸, Naomi Viapiana⁵, Alvise Berti⁹, Roberto Bortolotti⁹, Milena Bond¹⁰, Roberto Padoan¹¹, Mara Felicetti⁹, Franco Schiavon¹², Carlotta Nannini¹³, Fabrizio Cantini¹³, Alessandro Giollo¹⁴, Maurizio Rossini¹⁵, Edoardo Conticini¹⁶, Bruno Frediani¹⁷, Fabrizio Conti¹⁸, Roberta Priori¹⁸, Marco Sebastiani¹⁹, Giulia Cassone²⁰, Luca Quartuccio Quartuccio²¹, Elena Treppo²², Silvano Bettio²³, Ariela Hoxha²⁴, Marco Lovisotto²⁴, Giacomo Emmi²⁵, irene mattioli²⁶, Pietro Leccese²⁷, Roberto F. Caporali²⁸, Lorenza Maria Argolini²⁹, Rosario Foti³⁰, Elisa Visalli³⁰, Michele Colaci³¹, Carlomaurizio Montecucco³², Lorenzo Dagna³³ and Carlo Salvarani³⁴, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁵IRCCS San Raffaele Hospital, Milan, Italy, ⁶IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁷Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁸Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁹Santa Chiara Hospital of Trento, Trento, Italy, ¹⁰Azienda sanitaria dell'Alto Adige, Merano, Italy, ¹¹Department of Medicine DIMED, University of Padova, Padova, Italy, ¹²University of Padova, Padova, Italy, ¹³Santo Stefano Hospital Prato, Prato, Italy, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ¹⁵Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, ¹⁶Tallaght University Hospital, Dublin, Ireland, ¹⁷University of Siena, Siena, Italy, ¹⁸University of Rome La Sapienza, Rome, Italy, ¹⁹Azienda Policlinico di Modena, Modena, Italy, ²⁰University of Modena and Reggio Emilia, Modena, Italy, ²¹Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ²²Physician, Moimacco, Italy, ²³University of Padua, Treviso, Italy, ²⁴San Bortolo Hospital of Vicenza, Vicenza, Italy, ²⁵University of Florence, Florence, Italy, ²⁶University of Florence, Firenze, Italy, ²⁷Regional Hospital San Carlo, Potenza, Italy, ²⁸Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ²⁹ASST Gaetano Pini, Milano, Italy, ³⁰AOU San Marco, Catania, Catania, Italy, Catania, Italy, ³¹University of Catania, Catania, Italy, ³²Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy, ³³Ospedale San Raffaele, Milano, Italy, ³⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The 2022 classification criteria for giant cell arteritis (GCA) have been recently published. The aim of this study is to investigate whether the score…
Abstract Number: 0702 • ACR Convergence 2023
Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study
Yanint Raksadawan, Sabahat Usmani, Harigopal Sandhyavenu, Thatiana Schulze Goni, Jalpan Patel, Hafiz Muhammad Waqar Younas and Amro Taha, Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Cardiac disease has been known to be a major morbidity and mortality cause in vasculitis. Large vessel vasculitis is mostly associated with pericarditis, myocarditis…
Abstract Number: 1648 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice: 2023 Update
Christian Dejaco¹, Sofia Ramiro², Milena Bond³, Philipp Bosch⁴, Cristina Ponte⁵, Sarah Mackie⁶, Thorsten Bley⁷, Daniel Blockmans⁸, Sara Brolin⁹, Ertugrul Cagri Bolek¹⁰, Rebecca Cassie¹¹, Maria C Cid¹², Juan Molina-Collada¹³, Bhaskar Dasgupta¹⁴, Berit Dalsgaard Nielsen¹⁵, Eugenio De Miguel¹⁶, Haner Direskeneli¹⁷, Christina Duftner¹⁸, Alojzija Hocevar¹⁹, Anna Molto²⁰, Valentin Sebastian Schäfer²¹, Luca Seitz²², Riemer H.J.A. Slart²³ and Wolfgang Schmidt²⁴, ¹Azienda Sanitaria Alto Adige, Brunico, Italy, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Azienda sanitaria dell'Alto Adige, Merano, Italy, ⁴Medical University of Graz, Graz, Austria, ⁵Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Institute of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, Germany, ⁸Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ⁹Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden, ¹⁰1-Hacettepe University Vasculitis Research Centre, Ankara, Turkey/ 2-Vasculitis Translational Research Program, NIAMS, NIH, US, Ankara, Turkey, ¹¹n/a, Leicester, United Kingdom, ¹²Hospital Clinic Barcelona, Barcelona, Spain, ¹³Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁴Mid & South Essex University Hospitals NHS Foundation Trust; Southend University Hospital, Westcliff-on-sea, United Kingdom, ¹⁵Department of Internal Medicine, Horsens, Denmark, ¹⁶Hospital Universitario La Paz, Madrid, Spain, ¹⁷Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁸Medical University Innsbruck, Innsbruck, Austria, ¹⁹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ²⁰HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²²Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ²³University of Twente, Enschede, Netherlands, ²⁴Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany
Background/Purpose: Imaging recommendations for primary large vessel vasculitis (LVV) were developed in 2018. Several new studies have emerged since then, and an update of the…
Abstract Number: 2394 • ACR Convergence 2023
18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Paula V. Estrada-Alarcón¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maria. T Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galindez-Agirregoikoa¹⁰, javier Mendizábal¹¹, lydia Abasolo¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Patricia Moya¹⁵, patricia Moran Alvarez¹⁶, Vanesa Navarro¹⁷, Carles Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Alicia García²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸, Ricardo Blanco²⁹ and On Behalf of ARTESER Working Group³⁰, ¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Department of Rheumatology, Hospital Universitario Donostia, San Sebastián, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Basurto University Hospital, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²Hospital Clínico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Hospital Ramón y Cajal, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, Islas Canarias, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁰SER, Spain
Background/Purpose: Imaging studies in patients with giant cell arteritis (GCA) and suspected large vessel vasculitis (LVV) are sensitive, increasingly available, and less aggressive than temporal…
Abstract Number: 2411 • ACR Convergence 2023
C-X-C Motif Chemokine Receptor 4-targeted Molecular Imaging in Giant Cell Arteritis – a Head-to-head Comparison with FDG PET
Matthias Froehlich¹, Sebastian E. Serfling², Michael Gernert³, Konstanze V. Guggenberger⁴, Takahiro Higuchi², Samuel Samnick², Marc Schmalzing⁵, Andreas K. Buck², Thorsten Bley⁴ and Rudolf A. Werner², ¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Würzburg, Würzburg, Germany, ²Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany, ³Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, Germany, ⁴Institute of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, Germany, ⁵University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: 2-[18F]fluoro-2-deoxy-D-glucose(FDG) is the reference PET radiotracer for detecting inflammation in giant cell arteritis (GCA). C-X-C motif chemokine receptor 4 (CXCR4)-directed PET, however, allows for…
Abstract Number: 2562 • ACR Convergence 2023
Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study
Adrien Cottu¹, Alessandro Tomelleri², Corrado Campochiaro³, Alexandra Forestier⁴, Jérémie Dion⁵, Milena Bond⁶, Ariane Laparra-ramakichenin⁷, Aline Gury⁸, Xavier Savary⁹, Robin Dhote¹⁰, Albrecht Betrains¹¹, Laurence Bouillet¹², Eric Liozon¹³, Eva Bories¹⁴, Arthur Petitdemange¹, Paul Legendre¹⁵, Benjamin Crichi¹⁶, Philippe Kerschen¹⁷, Lucie Carneiro-Esteves¹⁸, Lucile Grange¹⁸ and Benjamin Terrier¹⁹, ¹Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ⁴Department of Medical Oncology, Centre Oscar Lambret, Lille, France, ⁵Internal Medicine Department, Toulouse University Hospital, Toulouse, France, ⁶Azienda sanitaria dell'Alto Adige, Merano, Italy, ⁷Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France, ⁸Department of Internal Medicine, Arras GHAT, Arras, France, ⁹Department of Internal Medicine, Brest CHU Hospital, Brest, France, ¹⁰Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, ¹¹Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹²Internal medicine department, Grenoble University Hospital, Grenoble, France, ¹³Department of Internal Medicine, University Hospital of Limoges, Limoges Cedex, Limoges, France, ¹⁴Department of Internal Medicine, Purpan CHU Hospital, Toulouse, France, ¹⁵Department of Clinical Immunology, Centre hospitalier du Mans, Le Mans, France, ¹⁶Department of Internal Medicine, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ¹⁷Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, ¹⁸Department of Internal Medicine, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France, ¹⁹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICIs) have dramatically improved the prognosis for many cancers. The therapeutic effect of ICIs is based on their ability to release…
Abstract Number: 0703 • ACR Convergence 2023
Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis
Alicia Rodriguez-Pla, Sierra Pacific Arthritis and Rheumatology Centers, Fresno, CA
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients with the most common subtypes of primary systemic vasculitides. We aimed to estimate…
Abstract Number: 1649 • ACR Convergence 2023
Follow-up Ultrasound Examination in Patients with Newly Diagnosed Giant Cell Arteritis
Lara Clarissa Burg¹, Christian Dejaco², Pantelis Karakostas³, Charlotte Behning⁴, Peter Brossart¹ and Valentin Sebastian Schäfer³, ¹University Hospital of Bonn, Bonn, Germany, ²Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ³Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ⁴Institute of Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, Bonn, Germany
Background/Purpose: In recent years, ultrasound has become a standard tool in the diagnosis of giant cell arteritis (GCA). Typical findings are increased intima media thickness…
Abstract Number: 2396 • ACR Convergence 2023
Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis
Jean-Charles Mourot¹, Sai Yan Yuen², Mihaela Popescu³ and Nicolas Richard⁴, ¹Université de Montréal, Mont-Royal, QC, Canada, ²Maisonneuve-Rosemont Hospital, Mont-Royal, QC, Canada, ³Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, ⁴Hopital Maisonneuve Rosemont, Montreal, QC, Canada
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US)…
Abstract Number: 2412 • ACR Convergence 2023
Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice
María del Carmen San José Méndez¹, Uxía Couto Lareo¹, Vanesa Balboa Barreiro², Francisco J. Blanco¹, Bruno de aspe de la iglesia¹, Antonio Atanes Sandoval³, Diego Dios Santos¹, Jesús Carlos Fernández López¹, Mercedes Freire González¹, Guillermo González Arribas¹, Genaro Graña Gil¹, Natividad Oreiro Villar¹, Jose Antonio Pinto Tasende¹, Francisco Javier De Toro Santos¹, Clara Ventin Rodriguez¹, Maite silva díaz³ and Ana Lois Iglesias¹, ¹Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²Clinic epidemiology and biostatistics department. Complejo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain
Background/Purpose: Giant cell arteritis (GCA) affects large and medium size arteries. Biopsy was considered the gold standard in the diagnosis1, but in the last years…
Abstract Number: 2599 • ACR Convergence 2023
Study of the Role of interleukin-17 in Giant Cell Arteritis
helene Greigert¹, andre ramon², corentin Richard³, claudie cladière⁴, Marion CIUDAD⁵, catherine creuzot-garcher⁶, laurent martin⁷, Sylvain AUDIA¹, romain boidot³, Bernard Bonnotte¹ and Maxime Samson¹, ¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Department of Rheumatology, Dijon University Hospital, Dijon, France, ³Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Dijon, France, ⁶Department of Ophthalmology, Dijon University Hospital, Dijon, France, ⁷Department of Pathology, Dijon University Hospital, Dijon, France
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis in which Th17 cells have been identified in excess in lesions and in the blood of patients.…

« Previous Page
1
…
6
7
8
9
10
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].